Streetbeat News

Analyst Ratings

IMAX

B. Riley Securities analyst Eric Wold has maintained a Buy rating on Imax Corporation (NYSE:IMAX) but has reduced the price target from $27 to $21.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:26 pm

MRNA

Oppenheimer analyst Hartaj Singh upgraded Moderna Inc (NASDAQ:MRNA) to Outperform with a price target of $142, citing the company's potential to become a 'five-product commercial company' by 2026. Singh highlighted the expected approvals of Moderna's RSV vaccine (mRNA-1345), influenza vaccine (mRNA-1010), and INT (mRNA-4157), which could utilize the Accelerated Approval pathway. Despite a decline in COVID-19 vaccine sales, there's been an uptick in hospitalizations. Singh anticipates a decrease in OPEX for 2024 and 2025, with sales picking up in 2025. Moderna's shares were up 13.5% to $112.88 following the upgrade.

Portfolio Pulse from Priya Nigam

January 02, 2024 | 4:21 pm

AMC

B. Riley Securities analyst Eric Wold has maintained a Neutral rating on AMC Entertainment Holdings (NYSE:AMC) but has lowered the price target from $15 to $12.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:19 pm

MCS

B. Riley Securities analyst Eric Wood has maintained a Buy rating on Marcus Corporation (NYSE:MCS) but has reduced the price target from $23 to $19.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:16 pm

WD

Wedbush analyst Henry Coffey has maintained an Outperform rating on Walker & Dunlop (NYSE:WD) and increased the price target from $110 to $130, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:13 pm

ALKS

B of A Securities analyst Jason Gerberry has maintained a Neutral rating on Alkermes (NASDAQ:ALKS) and increased the price target from $27 to $29.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:12 pm

AOSL

Alpha and Omega Semiconductor (AOSL) shares are up following an upgrade from B. Riley Securities, which changed its rating from Neutral to Buy and increased the price target from $28 to $34.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:11 pm

PFSI

Wedbush analyst Henry Coffey has maintained an Outperform rating on PennyMac Financial Services (PFSI) and increased the price target from $85 to $105.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:09 pm

DOC

Compass Point analyst Merrill Ross has maintained a Buy rating on Physicians Realty Trust (NYSE:DOC) but has lowered the price target from $19 to $18.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:07 pm

ARWR

B of A Securities analyst Jason Gerberry has maintained a Buy rating on Arrowhead Pharma (NASDAQ:ARWR) and increased the price target from $29 to $37, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:07 pm